2、会议召集人：公司第五届董事会 3、会议召开的合法、合规性：本次股东大会的召集和召开符合《公 司法》《上市公司股东大会规则》等法律、法规和《公司章程》的有关规 定。 4、会议召开日期、时间： 证券代码：300314 证券简称：戴维医疗 公告编号：2025-027 宁波戴维医疗器械股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于2025年4月7 日召开的第五届董事会第十一次会议审议通过了《关于提请召开公司2024 年度股东大会的议案》，决定于2025年5月6日（星期二）14:00召开2024 年度股东大会，并于2025年4月9日在巨潮资讯网（www.cninfo.com.cn） 发布了《关于召开2024年度股东大会的通知》（公告编号：2025-022）， 本次股东大会将采取现场投票与网络投票相结合的方式召开，现将会议的 有关事项提示如下： 一、召开会议的基本情况 1、会议届次：2024 年度股东大会 现场会议召开时间：2025 年 5 月 6 日（星期二） ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-025 宁波戴维医疗器械股份有限公司 2025年第一季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司 2025 年第一季度报告于 2025 年 4 月 28 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025 年 4 月 28 日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥121,163,868.56, a decrease of 22.00% compared to ¥155,328,964.53 in the same period last year[5] - Net profit attributable to shareholders was ¥22,567,669.04, down 40.78% from ¥38,107,228.76 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0784, a decrease of 40.74% from ¥0.1323 in the same period last year[5] - Total operating revenue decreased to ¥121,163,868.56 from ¥155,328,964.53, representing a decline of approximately 22% year-over-year[20] - Net profit for the period was ¥22,567,669.04, down from ¥38,107,228.76, reflecting a decline of approximately 41% year-over-year[21] - Operating profit decreased to ¥25,840,397.43 from ¥44,488,936.73, a drop of around 42% year-over-year[21] - Earnings per share decreased to ¥0.0784 from ¥0.1323, reflecting a decline of approximately 41% year-over-year[22] Cash Flow - The net cash flow from operating activities was -¥32,239,761.88, representing a decline of 212.07% compared to -¥10,331,039.53 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥32,239,761.88, worsening from a net outflow of ¥10,331,039.53 in the previous period[23] - The net increase in cash and cash equivalents was -$48,415,502.37, compared to -$114,368,823.04 previously, showing a reduction in cash outflow[24] - The ending balance of cash and cash equivalents was $283,145,669.78, down from $443,087,497.54, indicating a decrease in liquidity[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,385,776,038.97, down 1.72% from ¥1,410,082,914.70 at the end of the previous year[5] - The company's total liabilities decreased from CNY 238,393,710.24 to CNY 189,056,321.62, reflecting a decline of about 20.7%[16] - Current liabilities decreased from CNY 232,387,523.93 to CNY 183,984,580.97, a reduction of approximately 20.7%[16] - The company's long-term equity investments decreased from CNY 50,327,967.68 to CNY 48,707,993.03, a decline of about 3.2%[17] - The total non-current assets decreased from CNY 508,368,642.73 to CNY 502,928,305.25, a decrease of approximately 1.1%[17] - Total liabilities decreased to ¥193,896,157.08 from ¥241,765,545.70, a reduction of approximately 20% year-over-year[18] Research and Development - Research and development expenses increased by 35.09% to ¥13,897,552.90 from ¥10,287,345.11 in the previous year[9] - Research and development expenses increased to ¥13,897,552.90 from ¥10,287,345.11, marking a rise of approximately 35% year-over-year[20] Other Income and Investments - The company received government subsidies amounting to ¥3,147,557.99, contributing to other income of ¥3,472,227.93, which increased by 151.35% year-on-year[9] - The company reported a significant increase in investment income, which rose by 213.94% to ¥2,910,678.58 compared to a loss of ¥2,554,623.67 in the previous year[9] - Other income rose to ¥3,472,227.93 from ¥1,381,449.45, an increase of about 152% year-over-year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,622[11] - The company reported a total of 144,258,552 shares under lock-up agreements, with a release schedule based on the previous year's holdings[14] - The company has a significant number of shares held by major shareholders, with the largest shareholder holding 98,946,150 shares[13] Accounts Receivable and Inventory - Accounts receivable rose by 42.96% to ¥37,774,667.28, primarily due to increased credit limits granted to distributors[9] - Accounts receivable increased from CNY 26,423,040.77 to CNY 37,774,667.28, reflecting an increase of approximately 42.9%[16] - Inventory rose from CNY 182,135,010.43 to CNY 195,169,622.42, indicating an increase of about 7.2%[16]

| 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0784 | 0.1323 | -40.74 | 0.1737 | | 每股净资产（元） | 0 | 4.17 | -100 | 3.85 | | 每股公积金(元) | 0.61 | 0.61 | 0 | 0.61 | | 每股未分配利润(元) | 2.21 | 2.26 | -2.21 | 1.97 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.21 | 1.55 | -21.94 | 1.58 | | 净利润(亿元) | 0.23 | 0.38 | -39.47 | 0.5 | | 净资产收益率(%) | 1.91 | 3.22 | -40.68 | 4.61 | | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 陈再宏 | 3298.21 | 22.95 | 不变 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-024 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年4月21日 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日取得由浙江省药品监督管理局颁发 的《中华人民共和国医疗器械变更注册（备案）文件》，公司产品一次性 使用肛肠吻合器完成了医疗器械产品注册变更，具体情况如下： 一、医疗器械注册证变更具体情况 | 1 | 一次性使用肛肠吻合 | 浙械注准 20152020238 | Ⅱ类 | 因材料变更等涉及的产 | | --- | --- | --- | --- | --- | | 序号 | 产品名称 器 | 注册证编号 | 注册分类 | 主要变更内容 品技术要求变更 | 二、对公司的影响及风险提示 上述医疗器械注册证"产品技术要求"的变更，符合公司的生产经营 实际，对公司发展具有积极影响，但尚无法预测上述变更事宜对公司未来 营业收入的影响，敬请广大投资者予以关注并注意投资风险。 本公司及董事会全体成员保证信息披露的内容真实、 ...

4月18日，戴维医疗今日收盘11.81元，下跌3.20%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到59.40倍，总市值34.01亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均43.49倍，行业中值29.26倍，戴维医疗排 名第99位。 股东方面，截至2025年4月10日，戴维医疗股东户数20500户，较上次减少122户，户均持股市值35.28万 元，户均持股数量2.76万股。 宁波戴维医疗器械股份有限公司的主营业务是儿产科保育设备、微创外科手术器械以及急救手术ICU产 品。公司的主要产品是婴儿培养箱、婴儿辐射保暖台、新生儿黄疸治疗设备、黄疸检测设备、脑电监测 仪、亚低温治疗仪、经皮黄疸仪、婴儿T组合复苏器、医用空氧混合器、医用电动吸引器、新生儿专用 监护仪、医用加热仪、医用婴儿床、电动腔镜吻合器、手动腔镜吻合器、开放系列吻合器。目前，公司 被国家工信部认定为"制造业单项冠军培育企业"，同时荣获"浙江省知名商号"、"浙江省信用管理示范 企业"、"资信等级AAA级企业"、"浙江省'专精特新'中小企业"、"宁波市'专精特新'中小企业"等多项荣 誉称号。 最新一期业绩显示，2024 ...

证券代码：300314 证券简称：戴维医疗 宁波戴维医疗器械股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 类别 | □媒体采访 ■业绩说明会 | | | | | | | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | | | | | □现场参观 | | | | | | | | | | | | | | □其他 （电话会议） | | | | | | | | | | | | | 参与单位名称及 | 线上参与公司 2024 年度网上业绩说明会的投资者 | | | | | | | | | | | | | 人员姓名 | | | | | | | | | | | | | | 时间 | 2025 月 日（星期三）15:00–17:00 | 年 | 4 | 16 | | | | | | | | | | 地点 | ...

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-023 一、医疗器械注册证的具体情况 产品名称：一次性使用腔镜用直线型切割吻合器及组件 型号、规格： 器身型号规格：YGSE46、YGCE46、YGLE46等YG系列，YMSE46、YMCE46、 YMLE46等YM系列；组件型号规格：YSCR46M、YSCR46W、YSCR46B等YS系列， YGCR46M、YGCR46W、YGCR46B等YG系列。 宁波戴维医疗器械股份有限公司 关于全资孙公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资孙公司宁 波甬星医疗仪器有限公司（以下简称"甬星医疗"）于近日收到浙江省药 品监督管理局颁发的1项《医疗器械注册证》，具体如下： 注册分类：Ⅱ类 适用范围：用于腔镜下普通外科、妇产科、泌尿外科、胸外科及儿科 手术的组织离断、切除和/或建立吻合。 四、风险提示 注册证编号：浙械注准20252021259 批准日期：2025年4月11日 有效期至：2030年4月10日 二、新产品的 ...

4月10日，戴维医疗今日收盘12.2元，上涨6.18%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到61.36倍，总市值35.14亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.15倍，行业中值29.13倍，戴维医疗排 名第99位。 最新一期业绩显示，2024年年报，公司实现营业收入5.27亿元，同比-14.76%；净利润5726.33万元，同 比-61.21%，销售毛利率56.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)99戴维医疗61.3661.363.0135.14亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1硕世生物-1773.70-1773.701.1136.64亿2诺唯 赞-508.88-508.882.3392.08亿3博晖创新-340.62-209.723.7552.28亿4康泰医学-270.0231.682.7652.52亿5华 大基因-198.46217.092.05201.67亿6奥精医疗-108.48-108.481.3819.65亿7睿昂基因-79.90-79.901.2 ...